News
For the most up to date news, please follow us on LinkedIn via the link below
Meet us at ACHEMA 2024
May 8, 2024
Make your lyophilization equipment Future-Proof!
Discover the latest developments in freeze-drying that help you meet the mark. Visit the RheaVita stand (18D85) and learn more from the driving force in pharmaceutical controlled and continuous lyophilization.
Looking forward to seeing you in Frankfurt from 10-14 June 2024.
The RheaVita team is ready for the premier pharmaceutical manufacturing event: INTERPHEX 24
March 26, 2024
From 16th to 18th April, our process specialists will be glad to present the latest developments: RheaLyo™ mono freeze-dryer: our Single Vial Unit for R&D. Fast formulation and process development. RheaLyo™ multi freeze-dryer: our machine for non-GMP stability batch productions. RheaLyo™ GMP-Flex™ production lines: for clinical and commercial productions.
Ghent University scientists launch CEPI-funded project ‘spin-freezing’ vaccines
March 11, 2024
Ghent University will receive up to US $1.9 million to test the performance of optimised mRNA vaccines, developed on the university’s specialised mRNA Galsomes platform, in preclinical models after ‘spin-freezing’ the vaccines. Pioneered by RheaVita, a spin-off company of Ghent University, spin-freezing is a novel alternative to the traditional freeze-drying method. The research will be supported by Flanders Institute for Biotechnology (VIB).
Download the White Paper describing how continuous aseptic freeze-drying can address the major pain points of pharmaceutical batch freeze-drying
February 14, 2024
We have created a White Paper describing how continuous aseptic freeze-drying can address the major pain points of pharmaceutical batch freeze-drying such as: time-consuming, inefficient, energy-consuming, and poorly controlled.
Download the White Paper on “Stabilizing mRNA LNPs via controlled, continuous freeze-drying”
February 9, 2024
Download the White Paper describing the advantages associated with a RheaVita’s NextGen continuous and controlled lyophilization.
Coriolis Pharma and RheaVita join forces in collaboration for continuous and controlled freeze-drying technology
July 31, 2023
Coriolis Pharma extends its service portfolio by integrating RheaVita’s single vial unit (SVU) technology for continuous and controlled freeze-drying to stabilize novel modalities as part of biologics drug product development for clients.